Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 17 studies | 31% ± 17% | |
astrocyte | 11 studies | 32% ± 16% | |
microglial cell | 11 studies | 26% ± 9% | |
oligodendrocyte precursor cell | 11 studies | 35% ± 15% | |
glutamatergic neuron | 10 studies | 49% ± 27% | |
macrophage | 10 studies | 31% ± 12% | |
oligodendrocyte | 10 studies | 28% ± 10% | |
GABAergic neuron | 9 studies | 46% ± 25% | |
interneuron | 6 studies | 48% ± 25% | |
epithelial cell | 6 studies | 29% ± 8% | |
amacrine cell | 5 studies | 26% ± 10% | |
neuron | 4 studies | 31% ± 11% | |
granule cell | 4 studies | 28% ± 8% | |
myeloid cell | 4 studies | 20% ± 3% | |
fibroblast | 4 studies | 27% ± 14% | |
adipocyte | 4 studies | 21% ± 3% | |
dendritic cell | 4 studies | 21% ± 8% | |
endothelial cell of lymphatic vessel | 4 studies | 23% ± 5% | |
GABAergic interneuron | 3 studies | 36% ± 1% | |
retinal ganglion cell | 3 studies | 34% ± 7% | |
B cell | 3 studies | 17% ± 1% | |
retinal cone cell | 3 studies | 23% ± 6% | |
cardiac muscle cell | 3 studies | 18% ± 1% | |
ciliated cell | 3 studies | 20% ± 3% | |
GABAergic amacrine cell | 3 studies | 28% ± 13% | |
glycinergic amacrine cell | 3 studies | 24% ± 8% | |
alveolar macrophage | 3 studies | 25% ± 8% | |
transit amplifying cell | 3 studies | 31% ± 18% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 14 studies | 37% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 1929.98 | 180 / 180 | 100% | 6.43 | 430 / 430 |
prostate | 100% | 2436.87 | 245 / 245 | 100% | 7.79 | 502 / 502 |
brain | 100% | 2572.28 | 2641 / 2642 | 100% | 7.69 | 705 / 705 |
esophagus | 100% | 1576.70 | 1444 / 1445 | 100% | 5.57 | 183 / 183 |
breast | 100% | 1801.20 | 459 / 459 | 100% | 6.43 | 1117 / 1118 |
thymus | 100% | 2536.07 | 653 / 653 | 100% | 6.26 | 604 / 605 |
adrenal gland | 100% | 2099.85 | 258 / 258 | 100% | 4.68 | 229 / 230 |
kidney | 100% | 1707.90 | 89 / 89 | 99% | 6.12 | 896 / 901 |
lung | 100% | 1796.25 | 578 / 578 | 99% | 5.29 | 1148 / 1155 |
uterus | 100% | 1978.34 | 170 / 170 | 99% | 5.63 | 454 / 459 |
pancreas | 99% | 878.71 | 326 / 328 | 99% | 3.15 | 176 / 178 |
skin | 100% | 1781.74 | 1809 / 1809 | 98% | 5.26 | 461 / 472 |
intestine | 100% | 1872.50 | 966 / 966 | 98% | 3.22 | 514 / 527 |
stomach | 100% | 1411.56 | 359 / 359 | 97% | 3.70 | 278 / 286 |
liver | 100% | 984.31 | 226 / 226 | 97% | 2.55 | 394 / 406 |
bladder | 100% | 1745.52 | 21 / 21 | 96% | 3.91 | 486 / 504 |
adipose | 100% | 1808.70 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 6.20 | 29 / 29 |
muscle | 100% | 2569.79 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2308.04 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 5.31 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.41 | 1 / 1 |
blood vessel | 100% | 1627.74 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 1366.85 | 849 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 93% | 3.36 | 74 / 80 |
peripheral blood | 71% | 1082.15 | 658 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0060766 | Biological process | negative regulation of androgen receptor signaling pathway |
GO_0006351 | Biological process | DNA-templated transcription |
GO_0016925 | Biological process | protein sumoylation |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0016605 | Cellular component | PML body |
GO_0005634 | Cellular component | nucleus |
GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
GO_0003677 | Molecular function | DNA binding |
GO_0019789 | Molecular function | SUMO transferase activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0005515 | Molecular function | protein binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0003712 | Molecular function | transcription coregulator activity |
GO_0061665 | Molecular function | SUMO ligase activity |
Gene name | PIAS2 |
Protein name | E3 SUMO-protein ligase PIAS2 (EC 2.3.2.-) (Androgen receptor-interacting protein 3) (ARIP3) (DAB2-interacting protein) (DIP) (E3 SUMO-protein transferase PIAS2) (Msx-interacting zinc finger protein) (Miz1) (PIAS-NY protein) (Protein inhibitor of activated STAT x) (Protein inhibitor of activated STAT2) Protein inhibitor of activated STAT 2 PIAS2 protein Protein inhibitor of activated STAT 2 (cDNA FLJ57366, highly similar to Protein inhibitor of activated STAT2) |
Synonyms | PIASX |
Description | FUNCTION: Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulator in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. The effects of this transcriptional coregulation, transactivation or silencing may vary depending upon the biological context and the PIAS2 isoform studied. However, it seems to be mostly involved in gene silencing. Binds to sumoylated ELK1 and enhances its transcriptional activity by preventing recruitment of HDAC2 by ELK1, thus reversing SUMO-mediated repression of ELK1 transactivation activity. Isoform PIAS2-beta, but not isoform PIAS2-alpha, promotes MDM2 sumoylation. Isoform PIAS2-alpha promotes PARK7 sumoylation. Isoform PIAS2-beta promotes NCOA2 sumoylation more efficiently than isoform PIAS2-alpha. Isoform PIAS2-alpha sumoylates PML at'Lys-65' and 'Lys-160'. . |
Accessions | O75928 ENST00000545673.5 ENST00000592212.5 ENST00000589917.1 ENST00000586953.1 K7EMP6 ENST00000398654.7 K7EJT4 K7EQX5 A0A087WUY7 K7ER97 Q2TA77 ENST00000324794.11 [O75928-2] A0A0A0MS92 ENST00000585916.6 [O75928-1] ENST00000592221.5 ENST00000587810.1 B4DGW0 |